The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers. A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.
Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.
The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.
Reducing the High Cost of Prescription Drugs in the U.S.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
In Partnership with
Overview
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Show more
In Partnership with
Overview
The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers. A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.
Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.
The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?